STOCK TITAN

Gyre Therapeutics (GYRE) COO sells shares after exercising options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GYRE Therapeutics Chief Operating Officer Ye Weiguo reported a small exercise-and-sell sequence in common stock. On May 18–19, he exercised stock options covering 9,320 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions at weighted average prices around $6.37 per share, within disclosed price ranges. Following these transactions, he directly holds 700,000 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Ye Weiguo
Role Chief Operating Officer
Sold 9,320 shs ($59K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 9,120 $0.00 --
Exercise Common Stock 9,120 $0.75 $7K
Sale Common Stock 9,120 $6.37 $58K
Exercise Stock Option (Right to Buy) 200 $0.00 --
Exercise Common Stock 200 $0.75 $150.00
Sale Common Stock 200 $6.62 $1K
Holdings After Transaction: Stock Option (Right to Buy) — 927,115 shares (Direct, null); Common Stock — 709,120 shares (Direct, null)
Footnotes (1)
  1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.6102 to $6.6215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.3002 to $6.4119. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These options are vested in full.
Shares sold 9,320 shares Common stock open-market sales on May 18–19
Weighted avg sale price May 19 <money>$6.37</money> per share Common stock sales with prices from $6.3002 to $6.4119
Weighted avg sale price May 18 <money>$6.62</money> per share Common stock sales with prices from $6.6102 to $6.6215
Option exercise price <money>$0.75</money> per share Stock option exercises into common stock
Common shares held after 700,000 shares Directly owned GYRE common stock after transactions
Options exercised 9,320 options Stock Option (Right to Buy) converted into common stock
Option expiration date <date>2030-10-31</date> Expiration for the Stock Option (Right to Buy) series
open-market sale financial
"transaction_action: "open-market sale" for common stock sales"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" in derivative entries"
weighted average sale price financial
"The price reported represents the weighted average sale price per share."
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ye Weiguo

(Last)(First)(Middle)
C/O GYRE THERAPEUTICS, INC.
12730 HIGH BLUFF DRIVE, SUITE 250

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026M200A$0.75700,200D
Common Stock05/18/2026S200D$6.62(1)700,000D
Common Stock05/19/2026M9,120A$0.75709,120D
Common Stock05/19/2026S9,120D$6.37(2)700,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.7505/18/2026M200 (3)10/31/2030Common Stock200$0936,235D
Stock Option (Right to Buy)$0.7505/19/2026M9,120 (3)10/31/2030Common Stock9,120$0927,115D
Explanation of Responses:
1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.6102 to $6.6215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.3002 to $6.4119. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. These options are vested in full.
/s/ Weiguo Ye05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did GYRE COO Ye Weiguo report?

Ye Weiguo reported exercising stock options for 9,320 GYRE common shares and selling the same number in open-market trades. These transactions occurred on May 18–19 and are recorded as option exercises followed by open-market sales.

How many GYRE shares did the COO sell in this Form 4 filing?

The COO sold 9,320 shares of GYRE common stock in total. The sales were split between 200 shares on May 18 and 9,120 shares on May 19, all reported as open-market transactions with weighted average sale prices disclosed.

At what prices were the GYRE shares sold by the COO?

The reported weighted average sale prices were about $6.62 per share on May 18 and about $6.37 per share on May 19. Footnotes state the individual trades occurred within narrow ranges around these averages for each trading day.

What was the stock option exercise price in the GYRE Form 4?

The Form 4 shows stock options exercised at an exercise price of $0.75 per underlying GYRE common share. Each of the option exercises on May 18 and May 19 covered 200 and 9,120 shares respectively at this same $0.75 per share exercise price.

How many GYRE common shares does the COO hold after these trades?

After the reported option exercises and sales, the COO directly holds 700,000 shares of GYRE common stock. This post-transaction holding figure is disclosed in the non-derivative transaction table for common stock in the Form 4 filing.

What do the Form 4 footnotes say about GYRE share sale prices?

The footnotes explain that the reported sale prices are weighted averages. Shares sold on May 18 traded between $6.6102 and $6.6215, while those on May 19 traded between $6.3002 and $6.4119, with full trade-by-trade details available upon request.